

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Zanubrutinib	BTK inhibitor	CLL/SLL				US, EU (CLL), and other regions
		WM				US, EU, and other regions
		R/R FL				US, EU, and other regions
		R/R MZL				US, EU, and other regions
		TN MCL				
		R/R MCL				US and other regions
		R/R DLBCL with CD79B				
		Previously treated B-cell malignancies				
Zanubrutinib (Immunology & Inflammation)	BTK inhibitor	Primary membranous nephropathy				
		Lupus nephritis				
Sonrotoclax	BCL2 inhibitor	TN CLL ^a				
		R/R WM				
		R/R CLL				
		R/R MCL				
		R/R MM with t(11;14)				
		AML/MDS				
		B-cell malignancies				
BGB-16673	BTK-targeted CDAC	B-cell malignancies				
		R/R MCL and R/R CLL				
BGB-21447	BCL2 inhibitor	B-cell malignancies				
Tislelizumab	anti-PD-1	R/R cHL				China
Ociperlimab	anti-TIGIT	R/R DLBCL				

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MZL, marginal zone lymphoma; PD-1, programmed cell death protein 1; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; WM, Waldenström macroglobulinemia.

^aIn combination with zanubrutinib.

FOR MORE INFORMATION ON APPROVED USES IN YOUR REGION/COUNTRY, CONTACT A BEIGENE REPRESENTATIVE OR MEDICALINFORMATION@BEIGENE.COM

0120-BGB-A283-MRC-001

May 2024